Atul Saran - Emergent Biosolutions President
| EBS Stock | USD 9.15 0.04 0.44% |
President
Mr. Atul Saran is Executive Vice President, Corporationrationrate Development, General Counsel and Corporationrationrate Secretary of the company. Prior to joining Emergent, Mr. Saran served as senior vice president and general counsel at MacroGenics, Inc., from April 2014 to May 2017. Previously, Mr. Saran served in various leadership roles at AstraZeneca plc, and MedImmune, LLC, from 2003 through 2014, including vice president, corporate development and ventures at AstraZeneca and chairman of the MedImmune Ventures investment committee from May 2013 to January 2014 senior vice president, corporate development and ventures from January 2011 to May 2013 and positions of increasing responsibility in the MedImmune legal department from 2003 through 2010, culminating as vice president and deputy general counsel. Before his time at MedImmune, Mr. Saran was an associate attorney in the business and finance group at Hogan Hartson LLP. Mr. Saran is a board member of LogicNets, Inc., a private company. He previously served on the boards of directors for VentiRx Pharmaceuticals, Inc., Xencor, Inc., Inotek Pharmaceuticals, Inc. and Arriva Pharmaceuticals, Inc since 2022.
| Age | 51 |
| Tenure | 3 years |
| Professional Marks | MBA |
| Address | 300 Professional Drive, Gaithersburg, MD, United States, 20879 |
| Phone | 240 631 3200 |
| Web | https://www.emergentbiosolutions.com |
Emergent Biosolutions Management Efficiency
The company has Return on Asset of 0.0503 % which means that on every $100 spent on assets, it made $0.0503 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.3024 %, implying that it generated $0.3024 on every 100 dollars invested. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.2 in 2025. Return On Capital Employed is likely to gain to -0.08 in 2025. At this time, Emergent Biosolutions' Non Current Assets Total are comparatively stable compared to the past year. Other Assets is likely to gain to about 7.6 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 18 M in 2025.Similar Executives
| Found 11 records | PRESIDENT Age | ||
| David Urbanek | Elanco Animal Health | 57 | |
| James Meer | Elanco Animal Health | 55 | |
| Robert JD | Quidel | 55 | |
| Sarena Lin | Elanco Animal Health | 48 | |
| Shiv ONeill | Elanco Animal Health | 50 | |
| David Kinard | Elanco Animal Health | 58 | |
| Ramiro Cabral | Elanco Animal Health | 53 | |
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Todd Young | Elanco Animal Health | 52 | |
| Aaron Schacht | Elanco Animal Health | 52 | |
| Kevin Fitzgerald | Alnylam Pharmaceuticals | 57 | |
Management Performance
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.0503 |
Emergent Biosolutions Leadership Team
Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Warfield, Senior Development | ||
| Sean Kirk, Executive Vice President - Manufacturing and Technical Operations | ||
| William Hartzel, Senior Bioservices | ||
| Robert Burrows, IR Contact Officer | ||
| Stephanie Duatschek, Senior Officer | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Haywood Miller, Interim Officer | ||
| Kathryn Zoon, Independent Director | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Karen Smith, Executive Vice President Chief Medical Officer | ||
| Paul Williams, Senior Business | ||
| Keith Katkin, Independent Director | ||
| Simon MD, Chief Development | ||
| Jessica Perl, Corporate Counsel | ||
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Richard MBA, CFO VP | ||
| Jennifer Fox, Executive Vice President - External Affairs, General Counsel, Corporate Secretary | ||
| Katherine Strei, Executive Vice President - Human Resources and Communications, Chief Human Resources Officer | ||
| Michelle Pepin, Senior Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Coleen Glessner, Executive Compliance | ||
| Lynn Kieffer, VP Communications | ||
| Joseph Papa, CEO President | ||
| Papa MBA, President CEO | ||
| Marvin White, Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Robert Sr, Pres CEO | ||
| Adam Havey, Executive VP and President of Biodefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Non-Executive Independent Chairman of the Board | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
Emergent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.3 | ||||
| Return On Asset | 0.0503 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0 % | ||||
| Current Valuation | 890.8 M | ||||
| Shares Outstanding | 53.35 M | ||||
| Shares Owned By Insiders | 2.84 % | ||||
| Shares Owned By Institutions | 70.27 % | ||||
| Number Of Shares Shorted | 8.86 M | ||||
| Price To Earning | 1.67 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.